LIPELLA PHARMACEUTICALS INC. (LIPO)
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lipella Pharmaceuticals Inc.
OTC:LIPOHealthcare · Biotechnology
$0.0006
CLOSED · Nov 11Prev close$0.0005Close$0.0006
Mkt Cap$3K
EV-
Float4.4M
O/S4.62M
VOL43K sh
$ Vol$26
RVOL5.50×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
MCap$3KFloat4.4MO/S4.62M
Dilution
No press releases found for LIPO.